In preclinical systolic dysfunction, defined as left ventricular systolic dysfunction with no heart failure signs or symptoms, impairment in cardiorenal response to volume expansion may lead to symptomatic heart failure. Rescue of this impaired process in preclinical disease may prevent development of symptomatic heart failure.
Future studies are needed to further define the physiological effects and long-term outcomes of phosphodiesterase-V inhibition and exogenous BNP administration. Understanding the cardiorenal effects and outcomes of combination phosphodiesterase-V with exogenous B-type natriuretic peptide may affect the clinical management of patients with preclinical systolic dysfunction and renal dysfunction. along the HF spectrum (5) . Cyclic 3 0 -5 0 -guanosine monophosphate (cGMP) is the second messenger of the NP system, is metabolized by type V phosphodiesterase (PDEV), and plays an important role in the preservation of myocardial, vascular, and renal function in PSD and HF (6) . Previous animal studies have supported the therapeutic role of PDEV inhibitors in cardiac dysfunction (7) .
We recently reported that the cGMP signaling pathway is impaired in subjects with PSD, characterized by decreased glomerular filtration rate (GFR) and renal blood flow (RBF), with an attenuated renal The objective of our study was to assess, for the first time in subjects with PSD and renal dysfunction, T a d a l a fi l a n d S C p l a c e b o . Subjects randomized to receive tadalafil and SC placebo had no significant change in systolic blood pressure or heart rate with acute saline VE compared with baseline ( Wan et al. Table 2 ).
We also evaluated for a correlation between baseline GFR and outcomes. There was a negative correlation between baseline GFR and RPF, and a trend toward negative correlation for urine flow and GFR (p ¼ 0.05 as cutoff for statistical significance) (Supplemental Table 3 ). Differential Cardiac Versus Renal Response to Volume Expansion D E C E M B E R 2 0 1 9 : 9 6 2 -7 2 ADVERSE EVENTS. None of the subjects who received tadalafil and SC placebo had adverse events.
In the treatment group, after administration of tadalafil and SC BNP, 2 subjects (10%) experienced nausea and/or vomiting on the first morning of the study, 1 (5%) had transient chest discomfort that resolved spontaneously, and 1 (5%) had hypotension that subsequently resolved with saline infusion.
DISCUSSION
The present study was the first-in-human study to define the acute cardiorenal effects of combination tadalafil and SC BNP in response to VE in subjects with PSD and renal dysfunction. Based on our preclinical studies, we hypothesized that the combination of tadalafil and SC BNP would enhance the cardiorenal response to VE in subjects with PSD with renal dysfunction versus tadalafil alone. In this cohort of subjects with PSD and renal dysfunction, pre-treatment with tadalafil and SC BNP before VE resulted in improved cardiac function compared Abbreviations as in Tables 1 and 2 . to 50%. It is a common entity that affects approximately 3% to 6% of the general adult population of the United States, and it is more common among men and those with cardiovascular comorbidities (e.g., coronary artery disease and hypertension) (2, 14) . PSD is associated with increased mortality and cardiovascular events, and the annual incidence of progression from PSD to symptomatic HF is approximately 5% to 20% (14) (15) (16) . Neurohormonal activation plays an important role in the progression along the HF spectrum. The neurohumoral substudy of the SOLVD (Studies of Left Ventricular Dysfunction) cohort demonstrated a significant increase in neurohumoral activation in the symptomatic cohort compared with the prevention cohort (i.e., PSD) (12) .
The neurohumoral profile of the present cohort was similar to those in the SOLVD prevention cohort, with a mild activation of the NP system without activation of the renin angiotensin aldosterone system. Impaired sodium excretion to sodium load is a pathognomonic feature of clinical congestive HF (17) . With normal physiology, when renal perfusion and sodium delivery to the kidneys is reduced, renin is released, which eventually stimulates aldosterone, which results in sodium retention.
Those with symptomatic HF have excessive reninangiotensin-aldosterone activation, and subsequent salt retention and inability to excrete sodium load, which leads to increased intra-and extravascular volume (18) . This leads to typical HF symptoms, including dyspnea and edema. We previously reported that there is impaired renal response to VE in patients with PSD compared with normal subjects (8) . Renal cGMP activation was paradoxically decreased with attenuated urinary sodium excretion in subjects with PSD when exposed to acute VE compared with normal subjects. However, when exogenous SC BNP was administered before acute VE, the patients with PSD experienced an increase in urinary cGMP and natriuresis similar to subjects without underlying cardiac or renal dysfunction (19, 20) . However, combination tadalafil and BNP also led to decreased blood pressures and reduced renal perfusion, which might explain why there was worsened renal function. There was a differential cardiac versus renal response to VE with combination of tadalafil and BNP in subjects with PSD and renal dysfunction.
